Novo Nordisk A/S
NVOHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. The $172.28B market capitalization puts NVO squarely in large-cap range for its industry. It operates through two segments, Obesity and Diabetes Care, and Rare Disease.
Market Cap
$172.28B
Beta
0.38
P/E (TTM)
9.55
P/E (Fwd)
11.35
EPS (TTM)
$4.09
EPS (Fwd)
$3.44
ROE
59.8%
ROA
18.7%
Cash
$44.98B
Total Debt
$140.13B
Free CF
$37.67B
52W Change
-26.2%
Annual Financials
Cash vs Debt
Where NVO stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, NVO finished 10.07% below its 150-day moving average ($42.90) and 12.97% below its 200-day moving average ($44.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVO overbought or oversold?
At the October 13, 2026 close, NVO's RSI(14) was 41.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Novo Nordisk A/S carries $140.13B in total debt against $44.98B in cash reserves — debt is roughly 3.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $37.67B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 59.8%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 18.7% further supports the picture of efficient asset utilization. Revenue has grown from $176.95B (2022) to $309.06B (2025), reflecting a 75% increase over the period.
NVO's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Novo Nordisk A/S's trajectory.